格隆汇1月9日丨环旭电子(601231.SH)公布，为助力公司把握人工智能发展机遇，强化公司在前沿技术 领域的布局，2026年1月9日，公司与天津文仲投资管理有限公司及其他12位合伙人共同签署了《天津海 河曜仲股权投资合伙企业(有限合伙)合伙协议》，公司拟作为有限合伙人，投资天津海河曜仲股权投资 合伙企业(有限合伙),出资额人民币3000万元。本基金的目标募集规模为10亿元，最终规模由管理人自行 决定，预计不超过人民币15亿元，首期募集资金规模为61,250万元。基金的普通合伙人、执行事务合伙 人为文仲投资，管理人为苏州维特力新创业投资管理有限公司。 投资基金的投资领域：AI为核心的新一代信息技术产业，包含但不限于半导体、基础软件以及 AI 推理 相关领域、AI 相关的数据应用产业、新一代基础材料、高端制造业中可大规模应用的机器人领域等战 略新兴产业进行投资，投资阶段以早期至成长期为主，并配置部分成熟期项目。 ...

环旭电子（601231）(601231.SH)发布公告，为助力公司把握人工智能发展机遇，强化公司在前沿技术 领域的布局，公司拟作为有限合伙人，投资天津海河曜仲股权投资合伙企业(有限合伙)，出资额3000万 元。该基金的目标募集规模为10亿元，最终规模由管理人自行决定，预计不超过15亿元，首期募集资金 规模为61250万元。基金的普通合伙人、执行事务合伙人为文仲投资，管理人为苏州维特力新创业投资 管理有限公司。 ...

Group 1 - China Shipbuilding Defense expects a net profit of 940 million to 1.12 billion yuan for 2025, an increase of 149.61% to 196.88% year-on-year [1] - China First Heavy Industries has only undertaken a small number of related accessory projects and has not generated revenue from them [2] - Huanyu Electronics plans to invest 30 million yuan in a private equity fund focused on AI and emerging industries [3] Group 2 - Zhixiang Jintai's GR1803 injection has been included in the priority review list by the National Medical Products Administration [4] - JianKai Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [5] - Debon Holdings will continue to suspend trading from January 12 due to significant matters being planned [6] Group 3 - South Network Technology's shareholder intends to transfer 847.05 million shares, accounting for 1.50% of the total share capital [7] - Hengrui Medicine has received approval for clinical trials of four drugs [8] - Daotong Technology expects a net profit of 900 million to 930 million yuan for 2025, a year-on-year increase of 40.42% to 45.10% [10] Group 4 - Betta Pharmaceuticals has invested 50 million yuan to acquire a 20% stake in Hangzhou Zhixing Pharmaceutical [11] - Tianyu Biology reported a 10.38% year-on-year decline in cumulative sales revenue for 2025 [12] - Lifang Pharmaceutical's subsidiary has obtained a drug registration certificate for a pain relief product [13] Group 5 - R&F Properties reported a total sales revenue of approximately 14.21 billion yuan for 2025 [14] - Wanfu Biology expects a net profit decline of 87.71% to 91.81% for 2025 [15] - Dazhi expects a negative net profit for 2025 [16] Group 6 - Dongzhu Ecology is negotiating to terminate the acquisition of control over a satellite communication company [17] - Baotai has received a milestone payment of 10 million USD from Hikma Pharmaceuticals [18] - Huace Navigation expects a net profit of 670 million to 690 million yuan for 2025, a year-on-year increase of 14.84% to 18.27% [19] Group 7 - Shenzhen Gas reported a net profit decline of 3.45% for 2025 [20] - Baogang Co. plans to adjust the price of rare earth concentrate for Q1 2026 to 26,834 yuan per ton [21] - Jiuding Investment expects to report a loss for 2025 [22] Group 8 - Shanghai Pharmaceuticals has received a drug registration certificate for a treatment for myasthenia gravis [23] - Hualan Biological plans to acquire a 35% stake in Guangfeng Capsule [24] - Ruina Intelligent plans to invest 169.9 million yuan in a new R&D production base for heat pumps [25] Group 9 - Wantong Development expects to report a loss for 2025 [26] - Xianghe Industrial has completed the purchase of a 5% stake in Hezhixiang Technology [27] - Guangkang Biochemical received a warning letter from the Guangdong Securities Regulatory Commission [28] Group 10 - Xiaoming Co. reported a 37.07% year-on-year decline in chicken product sales revenue for December 2025 [29] - Luokai Co. won a procurement project from State Grid Fujian Power worth approximately 48.2 million yuan [30] - Minhe Co. reported a 65.22% year-on-year increase in the sales of commodity chick seedlings for December 2025 [31] Group 11 - Zhenghai Biological has obtained a registration certificate for calcium silicate bio-ceramic materials [32] - Three Gorges Energy reported a 5.99% year-on-year increase in cumulative total power generation for 2025 [33] - Huisheng Biological expects a net profit of 235 million to 271 million yuan for 2025 [34] Group 12 - Maihe Co. announced the release of the detention measures against its chairman [35] - Wandong's Alzheimer's project has been included in a national major special project for innovative drug development [36] - Kangxin New Materials plans to transfer forest land assets with a book value of 1.203 billion yuan [37] Group 13 - Greenland Holdings expects a net loss of 16 billion to 19 billion yuan for 2025 [39] - Zhongxin Fluorine Materials has obtained a pesticide production license [40]

证券代码：601231 证券简称：环旭电子 公告编号：2026-005 环旭电子股份有限公司 关于认购私募基金份额的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 与私募基金合作投资的基本情况：环旭电子股份有限公司（以下简称 "公司"）拟作为有限合伙人出资人民币 3,000 万元认购天津海河曜仲股权投 资合伙企业（有限合伙）（暂定名，以企业注册登记机关最终核准登记的名称 为准）的基金份额 交易实施尚需履行的审批及其他相关程序：关于使用自有资金开展企 业创投投资的事项已经公司董事会审议通过，本次投资事项属于经董事会决 议授权经营团队开展的企业创投投资，无需再次提交公司董事会及股东会审 议 特别风险提示：本次投资基金仍处于筹备设立阶段，后续尚需通过市 场监督管理部门及中国证券投资基金业协会等有关机构登记注册、备案等手 续，具体实施结果存在不确定性。基金投资具有投资周期长、流动性较低等 特点，本次投资将面临较长的投资回收期。合伙企业在后期运营过程中，所 投资项目可能受到宏观经济、行业周期、投资标的运营管理等多种 ...

Core Viewpoint - The company, Huanxu Electronics, announced its investment in a partnership focused on AI and emerging technologies, indicating a strategic move towards high-growth sectors [1] Investment Details - Huanxu Electronics will invest 30 million yuan as a limited partner in the Tianjin Haihe Yaozhong Equity Investment Partnership [1] - The target fundraising scale for the fund is set at 1 billion yuan, with a potential maximum of 1.5 billion yuan, and the initial fundraising amount is 613 million yuan [1] Investment Focus - The partnership aims to invest primarily in AI-centric new-generation information technology industries, including but not limited to semiconductors, foundational software, AI inference-related fields, AI data application industries, new foundational materials, and high-end manufacturing sectors with large-scale applications in robotics [1] - The investment strategy will focus on early to growth-stage projects, with a portion allocated to mature projects [1]

国泰海通证券股份有限公司 关于环旭电子股份有限公司 公开发行可转换公司债券 第一次临时受托管理事务报告 （2026 年度） 债券受托管理人 （住所：中国（上海）自由贸易试验区商城路 618 号） 二〇二六年一月 股票简称：环旭电子 股票代码：601231 债券简称：环旭转债 债券代码：113045 重要声明 本报告依据《可转换公司债券管理办法》《公司债券受托管理人执业行为准 则》《环旭电子股份有限公司公开发行可转换公司债券募集说明书》（以下简称《募 集说明书》）《环旭电子股份有限公司与海通证券股份有限公司之环旭电子股份有 限公司 2021 年可转换公司债券受托管理协议》（以下简称《受托管理协议》）等 相关规定、公开信息披露文件以及环旭电子股份有限公司（以下简称"公司"、 "环旭电子"或"发行人"）出具的相关说明文件以及提供的相关资料等，由受 托管理人国泰海通证券股份有限公司（以下简称"受托管理人"、"国泰海通"） 编制。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜做出独立判断，而不应将本报告中的任何内容据以作为国泰海通所作的承诺 或声明。在任何情况下，未经国泰海通书面许可，不得将 ...

证券代码：601231 证券简称：环旭电子 公告编号：2026-004 转债代码：113045 转债简称：环旭转债 环旭电子股份有限公司 2025年12月营业收入简报 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 特别提示：本简报所载财务数据为初步核算数据，未经会计师事务所审计，最终数据以公司定期报告为 准，请投资者注意投资风险。 环旭电子股份有限公司（以下简称"公司"）2025年12月合并营业收入为人民币4,766,677,706.23元，较去 年同期的合并营业收入减少7.79%，较2025年11月合并营业收入环比减少8.29%。 公司2025年1月至12月合并营业收入为人民币59,195,055,821.59元，较去年同期的合并营业收入减少 2.46%。 公司2025年第四季度（2025年10月至12月）合并营业收入为人民币15,553,880,279.79元，较去年同期的 合并营业收入减少6.77%，较第三季度（2025年7月至9月）合并营业收入环比减少5.32%。 环旭电子股份有限公司董事会 2026年1月9日 ...

证券日报网讯 1月8日，环旭电子（601231）发布公告称，公司2025 年 12 月合并营业收入为人民币 4， 766，677，706.23 元。 ...

Group 1 - Jinli Permanent Magnet expects a net profit of 660 million to 760 million yuan for 2025, representing a year-on-year growth of 127% to 161% [1] - Wens Foodstuffs anticipates a net profit of 5 billion to 5.5 billion yuan for 2025, a decrease of 40.73% to 46.12% compared to the previous year [2] - New Open Source plans to repurchase shares worth 40 million to 50 million yuan, with a maximum repurchase price of 25.77 yuan per share [3] Group 2 - Fosun Pharma's subsidiary has had a drug registration application accepted for a new drug targeting ALK-positive non-small cell lung cancer [4] - Leike Film reported a net profit of -86 million yuan for the first three quarters of 2025, indicating a potential annual loss [5] - Crown Stone Technology's application for a specific issuance of A-shares has been accepted by the Shanghai Stock Exchange [6] Group 3 - Dongxin Technology has completed the business registration change for its subsidiary, Lishuan Technology, and has invested 211 million yuan in it [7] - Tianci Materials has increased its commodity futures hedging business limit from 150 million to 300 million yuan [8] - Gaode Infrared's actual controller has reduced his shareholding by 0.54%, bringing his stake down to 62.95% [9] Group 4 - Tianyong Intelligent expects a net profit of 10 million to 15 million yuan for 2025, marking a turnaround from losses [10][11] - China Merchants Energy anticipates a net profit of 6 billion to 6.6 billion yuan for 2025, an increase of 17% to 29% year-on-year [18] - Guangdong Electric Power A's Huizhou Power Plant's Unit 5 has been put into commercial operation, with an investment of 8.05 billion yuan [19] Group 5 - Jianghuai Automobile reported a 42.24% year-on-year increase in sales volume for December 2025 [25] - China Pharmaceutical's subsidiary has received a drug registration certificate for a new medication [26] - TianNeng Co. plans to use up to 12 billion yuan of its own funds for entrusted wealth management [27] Group 6 - Luoyang Huizhong reported a 10.55% month-on-month decrease in sales revenue from live pigs for December 2025 [28] - Baolidi expects a net profit of 145 million to 152 million yuan for 2025, a year-on-year increase of 27.17% to 33.30% [30] - Changchun High-tech's subsidiary has had a melatonin granule registration application accepted [31] Group 7 - Zhongmin Energy reported a 4.46% year-on-year decrease in cumulative on-grid electricity for 2025 [32] - Huaxin Electronics reported a 7.79% year-on-year decrease in consolidated operating revenue for December 2025 [35] - Xiamen Airport reported a 2.79% year-on-year increase in passenger throughput for December 2025 [36] Group 8 - Baiyun Airport reported a 12.27% year-on-year increase in passenger throughput for December 2025 [37] - Pulaike has received a new veterinary drug registration certificate for a chewable tablet [38] - Yunnan Energy Holdings' subsidiary has reduced its stake to 84% after a capital increase [39] Group 9 - Gansu Energy Chemical's new thermal power project has successfully completed trial operation [41] - Zhenghong Technology reported a significant decrease in sales revenue from live pigs for December 2025 [42] - Huasheng Lithium Battery is planning to issue H-shares for listing on the Hong Kong Stock Exchange [43] Group 10 - Jincheng Mining has signed a mining production contract with an estimated total price of approximately 510 million yuan [44] - Microchip Biotech has received approval for clinical trials of a new drug for pancreatic cancer [45] - Yahon Pharmaceutical has completed the first patient enrollment for a Phase I clinical trial of its drug [46]

国泰海通证券股份有限公司 关于环旭电子股份有限公司 提前赎回"环旭转债"的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 环旭电子股份有限公司（以下简称"环旭电子"或"公司"） 公开发行可转换公 司债券的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所股 票上市规则》《可转换公司债券管理办法》《上海证券交易所上市公司自律监管指 引第1号——规范运作》等有关规定，对公司提前赎回"环旭转债"的事项进行 了核查，具体情况如下： 一、可转换公司债券基本情况 （一）可转债发行情况 经中国证券监督管理委员会《关于核准环旭电子股份有限公司公开发行可转 换公司债券的批复》（证监许可[2021]167号）核准，公司向社会公开发行 34,500,000张（3,450,000手）可转债，每张面值为人民币100元，共募集资金人民 币3,450,000,000元，扣除各项发行费用人民币19,273,584.91元及对应增值税人民 币1,156,415.09元后的募集资金净额为人民币3,429,570,000.00元。上述募集资金 已全部到位，经德勤华永会计师事务所（特殊普通合伙）审验，并出具了 ...